Journal
ESMO OPEN
Volume 7, Issue 1, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.esmoop.2021.100365
Keywords
nanomedicine; bloodebrain barrier; targeted therapy; pharmacokinetic; cerebrospinal fluid
Categories
Funding
- GoldschmidtJacobson Foundation
- Krebsliga Schweiz [KFS-412902-2017]
Ask authors/readers for more resources
This study evaluated the tolerability and effectiveness of anti-EGFR immunoliposomes in treating patients with relapsed glioblastoma harboring an EGFR amplification. The results showed that these immunoliposomes were unable to cross the blood-brain barrier, but could deliver drugs to glioblastoma tissue. In terms of efficacy, the median progression-free survival was 1.5 months and the median overall survival was 8 months.
Background: We assessed the capacity of epidermal growth factor receptor (EGFR)-targeted immunoliposomes to deliver cargo to brain tumor tissue in patients with relapsed glioblastoma harboring an EGFR amplification. We aimed to assess the tolerability and effectiveness of anti-EGFR immunoliposomes loaded with doxorubicin (antiEGFR ILs-dox) in glioblastoma multiforme patients. Patients and methods: Patients with EGFR-amplified, relapsed glioblastoma were included in this phase I pharmacokinetic trial. Patients received up to four cycles of anti-EGFR ILs-dox. Twenty-four hours later, plasma and cerebrospinal fluid (CSF) samples were obtained. In addition, we also treated three patients with anti-EGFR ILs-dox before resection of their relapsed glioblastoma. Doxorubicin concentrations were measured in plasma, CSF, and tumor tissue. Safety and efficacy parameters were also obtained. Results: There were no or negligible levels of doxorubicin found in the CSF demonstrating that anti-EGFR ILs-dox are not able to cross the bloodebrain barrier (BBB). However, significant levels were detected in glioblastoma tissue 24 h after the application, indicating that the disruption of BBB integrity present in high-grade gliomas might enable liposome delivery into tumor tissue. No new safety issues were observed. The median progression-free survival was 1.5 months and the median overall survival was 8 months. One patient undergoing surgery had a very long remission suggesting that neoadjuvant administration may have a positive effect on outcome. Conclusions: We clearly demonstrate that anti-EGFR-immunoliposomes can be targeted to EGFR-amplified glioblastoma and cargodin this case doxorubicindcan be delivered, although these immunoliposomes do not cross the intact BBB.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available